Which means that once we get confirmation of P1 trial results showing that the dosage of Brilacidin is indeed being delivered to the desired location in the colon to combat UC, then the odds of the P2a being successful go up tremendously.

That in my estimation is the beginning of when some BP may jump in with both feet to get the rights to B-IBD. Not saying it will happen, but it is the time they are all playing with fire in being too late with a bid to acquire such a highly valued drug with a wide, wide scope of valuable revenue streams.

Should have data results in Feb per PRs, the sooner the better.